汉森制药
(002412)
| 流通市值：33.60亿 | | | 总市值：33.97亿 |
| 流通股本：4.98亿 | | | 总股本：5.03亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 508,850,630.33 | 269,286,565.75 | 1,004,469,462.29 | 693,981,713.71 |
| 营业收入 | 508,850,630.33 | 269,286,565.75 | 1,004,469,462.29 | 693,981,713.71 |
| 二、营业总成本 | 372,994,919.63 | 201,370,449.78 | 772,586,431.75 | 554,722,346.7 |
| 营业成本 | 118,145,490.52 | 63,041,529.3 | 242,530,924.48 | 172,562,813.76 |
| 税金及附加 | 9,302,912.75 | 4,434,140.16 | 20,047,571.17 | 13,963,958.48 |
| 销售费用 | 190,200,177.63 | 105,233,393.58 | 400,316,267.61 | 294,411,101.54 |
| 管理费用 | 36,419,377.62 | 19,079,881.93 | 68,800,805.13 | 45,119,863.61 |
| 研发费用 | 18,508,706.85 | 9,330,205.66 | 39,322,290.36 | 27,453,358.32 |
| 财务费用 | 418,254.26 | 251,299.15 | 1,568,573 | 1,211,250.99 |
| 其中:利息费用 | 997,726.24 | 571,625.02 | 2,561,280.63 | 2,023,105.59 |
| 其中:利息收入 | 698,634.38 | 280,039.98 | 1,299,590.08 | 1,082,521.94 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 898,900.83 | 501,866.59 | 2,073,590.91 | 1,396,878.66 |
| 加:投资收益 | -39,497,582.73 | -45,279,555.05 | 9,972,397.05 | 4,740,181.17 |
| 资产减值损失(新) | 3,834.07 | 3,427.46 | -126,720.18 | -6,633.7 |
| 信用减值损失(新) | -2,668,841.78 | -1,681,797.57 | 359,091.21 | -1,713,877.95 |
| 其他收益 | 2,760,638.7 | 1,072,299.6 | 9,022,181.75 | 6,039,093.28 |
| 四、营业利润 | 97,352,659.79 | 22,532,357 | 253,183,571.28 | 149,715,008.47 |
| 加:营业外收入 | 136,426.24 | 50,720.33 | 835,772.53 | 452,520.53 |
| 减:营业外支出 | 503,839.35 | 473,487.79 | 1,262,761.83 | 612,256.34 |
| 五、利润总额 | 96,985,246.68 | 22,109,589.54 | 252,756,581.98 | 149,555,272.66 |
| 减:所得税费用 | 28,446,808.55 | 10,852,425.19 | 32,512,172.87 | 18,802,226.68 |
| 六、净利润 | 68,538,438.13 | 11,257,164.35 | 220,244,409.11 | 130,753,045.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 68,538,438.13 | 11,257,164.35 | 220,244,409.11 | 130,753,045.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 68,538,438.13 | 11,257,164.35 | 220,244,409.11 | 130,753,045.98 |
| 扣除非经常损益后的净利润 | 64,769,529.97 | 9,116,396.99 | 211,153,898.06 | 122,915,281.96 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | 0.02 | 0.44 | 0.26 |
| (二)稀释每股收益 | 0.14 | 0.02 | 0.44 | 0.26 |
| 八、其他综合收益 | -16,205,404.86 | -21,337,283.83 | 20,108,712.37 | 7,490,193.67 |
| 归属于母公司股东的其他综合收益 | -16,205,404.86 | -21,337,283.83 | 20,108,712.37 | 7,490,193.67 |
| 九、综合收益总额 | 52,333,033.27 | -10,080,119.48 | 240,353,121.48 | 138,243,239.65 |
| 归属于母公司股东的综合收益总额 | 52,333,033.27 | -10,080,119.48 | 240,353,121.48 | 138,243,239.65 |
| 公告日期 | 2025-08-26 | 2025-04-26 | 2025-04-26 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |